- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Future of Myelofibrosis: Anticipated Data and Emerging Therapies
Aaron Gerds, MD, MS, explores the future landscape of myelofibrosis with insights from the 2003 ASH Annual Meeting and Exposition (ASH 2023), and delves into anticipated data on combination therapies and ongoing trials shaping the next phase of myelofibrosis treatment.
EP: 1.Myelofibrosis: Characteristics and Subtypes
EP: 2.NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
EP: 3.Understanding Myelofibrosis: Disease Spectrum and Impact on Quality of Life
EP: 4.Prognosis and Treatment Strategies in Myelofibrosis: Risk Assessment and Therapeutic Goals
EP: 5.NCCN Guidelines 2023: Updates in Myelofibrosis Management
EP: 6.NCCN Guidelines: Categories and Recommendations in Myelofibrosis
EP: 7.Integrating Momelotinib: NCCN Guidelines and Drug Comparison
EP: 8.Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations
EP: 9.Future of Myelofibrosis: Anticipated Data and Emerging Therapies
This is a video synopsis/summary of a Guidelines involving Aaron Gerds, MD, MS.
Gerds anticipates significant data from ASH 2023 ,focusing on the transformative potential of combination therapies in myelofibrosis. The spotlight is on the TRANSFORM-1 (NCT04472598) and the MANIFEST-2 (NCT04603495) clinical trials, both exploring combination therapies. Despite achieving primary end points of spleen volume reduction, secondary end points related to symptom burden were not met, prompting nuanced interpretations. Gerds stresses the importance of long-term follow-up to assess the durability of combination therapies. Beyond ASH 2023, he highlights promising emerging treatments, including the MDM-2 inhibitor navtemadlin and the IMPACT study (NCT02164513) with imetelstat, aiming to prolong survival. Acknowledging the dynamic landscape of myelofibrosis treatment, Gerds advises practitioners to collaborate with specialized centers for optimal patient care and participation in clinical trials, which is crucial for advancing the field. This segment provides insights into the evolving therapeutic landscape for myelofibrosis and underscores the need for ongoing research and collaboration.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
NCCN Guidelines Prioritize Quad Therapy in Multiple Myeloma
November 26th 2024In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment option for transplant-eligible and -ineligible patients.
Read More
